JP2008546770A5 - - Google Patents

Download PDF

Info

Publication number
JP2008546770A5
JP2008546770A5 JP2008518084A JP2008518084A JP2008546770A5 JP 2008546770 A5 JP2008546770 A5 JP 2008546770A5 JP 2008518084 A JP2008518084 A JP 2008518084A JP 2008518084 A JP2008518084 A JP 2008518084A JP 2008546770 A5 JP2008546770 A5 JP 2008546770A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
alkoxy
hydrogen
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008518084A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008546770A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2006/000762 external-priority patent/WO2006137793A1/en
Publication of JP2008546770A publication Critical patent/JP2008546770A/ja
Publication of JP2008546770A5 publication Critical patent/JP2008546770A5/ja
Withdrawn legal-status Critical Current

Links

JP2008518084A 2005-06-22 2006-06-21 化合物iv Withdrawn JP2008546770A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0501468 2005-06-22
PCT/SE2006/000762 WO2006137793A1 (en) 2005-06-22 2006-06-21 New 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions

Publications (2)

Publication Number Publication Date
JP2008546770A JP2008546770A (ja) 2008-12-25
JP2008546770A5 true JP2008546770A5 (enExample) 2009-04-30

Family

ID=37570731

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008518084A Withdrawn JP2008546770A (ja) 2005-06-22 2006-06-21 化合物iv

Country Status (18)

Country Link
US (1) US20100048530A1 (enExample)
EP (1) EP1896458A4 (enExample)
JP (1) JP2008546770A (enExample)
KR (1) KR20080033265A (enExample)
CN (1) CN101223163A (enExample)
AR (1) AR057383A1 (enExample)
AU (1) AU2006259894A1 (enExample)
BR (1) BRPI0611616A2 (enExample)
CA (1) CA2609990A1 (enExample)
EC (1) ECSP088103A (enExample)
IL (1) IL187738A0 (enExample)
MX (1) MX2007016486A (enExample)
NO (1) NO20076196L (enExample)
RU (1) RU2007147346A (enExample)
TW (1) TW200726760A (enExample)
UY (1) UY29615A1 (enExample)
WO (1) WO2006137793A1 (enExample)
ZA (1) ZA200710606B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
ATE485267T1 (de) 2003-12-23 2010-11-15 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
UY29607A1 (es) * 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
AR057380A1 (es) * 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
AR057072A1 (es) 2005-06-22 2007-11-14 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
AR060623A1 (es) * 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−2,4−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
WO2008108486A1 (ja) * 2007-03-06 2008-09-12 Teijin Pharma Limited 1-ビアリールアゼチジノン誘導体
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010100255A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
BR112021002207A2 (pt) 2018-08-10 2021-05-04 Diapin Therapeutics, Llc tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
DE60229406D1 (de) * 2001-09-21 2008-11-27 Schering Corp Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US6761509B2 (en) * 2002-07-26 2004-07-13 Jan Erik Jansson Concrete module for retaining wall and improved retaining wall
US6960047B2 (en) * 2002-08-02 2005-11-01 Innovative Technology Application, Inc. Protection barrier apparatus
WO2004081002A1 (en) * 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7002008B2 (en) * 2003-06-16 2006-02-21 Bomi Patel Framroze Process for the preparation of 1-(4-fluorophenyl)-4(S)-(4-hydroxyphenyl)-azetidin-2-one
WO2005046797A2 (en) * 2003-11-05 2005-05-26 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
ATE485267T1 (de) * 2003-12-23 2010-11-15 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
JP2007516287A (ja) * 2003-12-23 2007-06-21 メルク エンド カムパニー インコーポレーテッド 抗高コレステロール血症化合物
KR100725758B1 (ko) * 2004-03-30 2007-06-08 삼성광주전자 주식회사 전동 송풍기 및 이를 이용한 자동차용 전동 과급기
US20060046996A1 (en) * 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
EP1807070A1 (en) * 2004-09-29 2007-07-18 Schering Corporation Combinations of substituted azetidinones and cb1 antagonists
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
US20070049748A1 (en) * 2005-08-26 2007-03-01 Uppala Venkata Bhaskara R Preparation of ezetimibe
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
US7498431B2 (en) * 2005-12-01 2009-03-03 Bomi Patel Framroze Process for the preparation of chiral azetidinones
AR060623A1 (es) * 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
WO2008033431A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders
WO2008108486A1 (ja) * 2007-03-06 2008-09-12 Teijin Pharma Limited 1-ビアリールアゼチジノン誘導体

Similar Documents

Publication Publication Date Title
JP2010501478A5 (enExample)
JP2011527334A5 (enExample)
JP2008525416A5 (enExample)
JP2007508359A5 (enExample)
JP2010540525A5 (enExample)
JP2007508362A5 (enExample)
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
JP2007534702A5 (enExample)
JP2016505586A5 (enExample)
JP2010526814A5 (enExample)
JP2008044952A5 (enExample)
JP2005053931A5 (enExample)
JP2012510502A5 (enExample)
JP2006143751A5 (enExample)
JP2009519243A5 (enExample)
JP2009535358A5 (enExample)
JP2006514626A5 (enExample)
JP2011513305A5 (enExample)
JP2010531293A5 (enExample)
JP2010520214A5 (enExample)
JP2012509265A5 (enExample)
JP2005517643A5 (enExample)
JP2013515037A5 (enExample)
JP2007519618A5 (enExample)
JP2007500222A5 (enExample)